Nektar Therapeutics
NKTR
227 hedge funds and large institutions have $693M invested in Nektar Therapeutics in 2022 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 79 increasing their positions, 59 reducing their positions, and 45 closing their positions.
439% more call options, than puts
Call options by funds: $3.92M | Put options by funds: $727K
34% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 59
0.24% more ownership
Funds ownership: 6.29% → 6.53% (+0.24%)
5% less funds holding
Funds holding: 239 → 227 (-12)
18% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 45
27% less capital invested
Capital invested by funds: $950M → $693M (-$257M)
Top Buyers
| 1 |
BlackRock
New York
|
+$23M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$14.5M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$13.2M |
| 4 |
State Street
Boston,
Massachusetts
|
+$12.3M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$5.64M |
Top Sellers
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$21.6M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$20.1M |
| 3 |
Millennium Management
New York
|
-$10M |
| 4 |
MC
Maverick Capital
Dallas,
Texas
|
-$6.62M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.6M |
NKTR Hedge Fund Activity: Q2 2022 in Review
227 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2022, worth a combined $693M — down 27% from $950M a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of NKTR and 37 opened new positions — a net loss of 8 holders — while 59 trimmed existing stakes and 79 added.
The largest buyer was BlackRock, adding an estimated $23M. The largest seller was Camber Capital Management, exiting entirely with an estimated $21.6M sold.
- 227 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2022, down from 239 in Q1 2022.
- Funds reported $693M of Nektar Therapeutics stock for Q2 2022, down 27% quarter-over-quarter.
- 37 funds opened new Nektar Therapeutics positions in Q2 2022 and 45 closed out, a net change of -8 holders.
- The largest Nektar Therapeutics buyer in Q2 2022 was BlackRock, an estimated $23M added.
- The largest Nektar Therapeutics seller in Q2 2022 was Camber Capital Management, an estimated $21.6M sold.
Based on aggregated 13F filings for Q2 2022.